AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drewnowski, A.
Right arrow Articles by Gosnell, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drewnowski, A.
Right arrow Articles by Gosnell, B. A.
Agricola
Right arrow Articles by Drewnowski, A.
Right arrow Articles by Gosnell, B. A.

American Journal of Clinical Nutrition, Vol 61, 1206-1212, Copyright © 1995 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters

A Drewnowski, DD Krahn, MA Demitrack, K Nairn and BA Gosnell
Program in Human Nutrition, University of Michigan School of Public Health, Ann Arbor, USA.

To test the hypothesis that endogenous opiate peptides selectively influence hedonic response to sweet and high-fat foods, the opiate antagonist naloxone, opiate agonist butorphanol, and a saline placebo were administered by intravenous infusion to 16 obese and 25 normal- weight women. Twenty of the women (10 obese, 10 lean) fulfilled DSM-III- R diagnostic criteria for bulimia nervosa, as determined by psychiatric interview. During drug infusion the women tasted and rated 20 sweetened dairy products and were presented with eight snack foods of varying sugar and fat content. Naloxone suppressed hedonic responses in all subject groups and suppressed the consumption of sweet and high-fat foods in binge eaters, but not in nonbingers. Food intakes of obese women were not affected by naloxone. Butorphanol had no effect on either hedonic response or on food consumption in any group. Although opiate blockade is not a viable strategy for weight reduction in the treatment of obesity, it may be useful in the clinical management of the binge-eating disorder.


This article has been cited by other articles:


Home page
 Alcohol AlcoholHome page
J. C. Garbutt, M. Osborne, R. Gallop, J. Barkenbus, K. Grace, M. Cody, B. Flannery, and A. B. Kampov-Polevoy
Sweet Liking Phenotype, Alcohol Craving and Response to Naltrexone Treatment in Alcohol Dependence
Alcohol Alcohol., May 1, 2009; 44(3): 293 - 300.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
S. Yanovski
Sugar and Fat: Cravings and Aversions
J. Nutr., March 1, 2003; 133(3): 835S - 837.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. S. Schiffman
Taste and Smell Losses in Normal Aging and Disease
JAMA, October 22, 1997; 278(16): 1357 - 1362.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by The American Society for Nutrition